Bloody Minded cover image

Episode 106 - Seal Team L | Chronic Lymphocytic Leukaemia (CLL)

Bloody Minded

00:00

Venetoclax and BTK Inhibitor Strategies

Nick and the hosts discuss obinutuzumab, rituximab, venetoclax ramp-up, tumor lysis risk, BTK inhibitor toxicities, resistance, and treatment sequencing.

Play episode from 35:14
Transcript

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app